healthcare policy

Drug launches in Europe drop 27% after Trump pricing order

Drugmakers that signed most-favored-nation (MFN) pricing deals with the Trump administration are now deciding where, and whether, to launch new medicines outside the US. Because a low price in one country can lower what a company is paid at home,…

You're all caught up

You've seen all the main stories from the past 2 days.